Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc > Paladin Labs' Revenue Guidance (2007-2012)

<< Previous

Bullboard Posts

Next >>

Post by gudisgoodon Apr 01, 2023 8:56am

309 Views

Post# 35373439

Paladin Labs' Revenue Guidance (2007-2012)

Just went through some of Paladin Labs' revenue guidance. In the years that I checked, they beat the midpoint of their initial revenue guidance every year. Here are the relative guidance beats: